Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure

被引:0
作者
M. Feola
L. Valeri
E. Menditto
E. Nervo
F. Bianco
N. Aspromonte
R. Valle
G. Visconti
机构
[1] Ospedale SS Trinità,Cardiovascular Rehabilitation
[2] “SS. Annunziata” Hospital,Heart Failure Unit
[3] “S. Croce-Carle” Hospital,Cardiology Division
[4] “S. Spirito” Hospital,Laboratory Analysis
[5] “Ospedale Civile”,Heart Failure Unit
来源
Journal of Endocrinological Investigation | 2010年 / 33卷
关键词
Brain natriuretic peptide; congestive heart failure;
D O I
暂无
中图分类号
学科分类号
摘要
This study compared two different methods, namely the immunoradiometric (IRMA) and fluorimetric (FIA), in order to determine plasma brain natriuretic peptide (BNP) in congestive heart failure (CHF) patients. Methods: CHF in-patients underwent echocardiography and plasma BNP determination using both two methods. The echocardiograms analysed left ventricular end-systolic (LVESV) and end-diastolic (LVEDV) volumes and systolic dysfunction [left ventricular ejection fraction (LVEF) <50%]. Results: Seventy-three (71% males, age 67±9.6 yr) patients were enrolled, 31.5% affected by valvular heart disease. The mean LVEF was 39.8±14.1%; in 26 (35%) a hypertensive etiology emerged. The immunoradiometric assay (IRMA) BNP was found to be significantly lower than the FIA determination 116.5±149 pg/ml vs 267.3±285.6 pg/ml; p=0.0001) and the two methods were closely correlated (r=0.89; p=0.00001). Logistic regression demonstrated a significant correlation between BNP, LVEF, and LVESV/LVEDV (r=−0.45, p=0.0003; r=−0.48, p=0.00001; r=0.22 p=0.003; r=0.34 p=0.0001; r=0.13 p=0.02; r=0.28 p=0.001 IRMA and FIA, respectively). IRMA BNP and FIA BNP significantly increased according to the worsening functional class [from 34.3±60.2 pg/ml in NYHA (New York Heart Association) I to 555.5±273.1 pg/ml in NYHA IV; from 86.1 ±162.1 pg/ml in NYHA I to 1070±42.2 pg/ml in NYHA IV, respectively]. In severe systolic dysfunction (LVEF<30%), receiver operating characteristic analysis revealed a satisfactorily sensitivity and specificity using a cut-off point of 50.6 pg/ml with IRMA and 243 pg/ml with FIA. In mild systolic dysfunction (LVEF<50%), a good sensitivity and specificity using a cut-off point of 42 pg/ml with IRMA and 182 pg/ml with FIA emerged. Conclusions: In CHF patients both BNP methods correlated with NYHA class, LVEF, and ventricular volumes.
引用
收藏
页码:554 / 558
页数:4
相关论文
共 92 条
  • [1] de Lemos JA(2003)B-Type natriuretic peptide in cardiovascular disease Lancet 362 316-22
  • [2] McGuire DK(2002)Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 359 5-6
  • [3] Drazner MH(2001)The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure Clin Chem Lab Med 39 571-88
  • [4] Richards AM(2001)B-Type natriuretic peptide levels: a potential novel “white count” for congestive heart failure J Card Fail 7 183-93
  • [5] Lainchbury JG(2002)Pathofisiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? Clin Chem Lab Med 40 752-60
  • [6] Nicholls MG(2005)Prognostic value of plasma brain natriuretic peptide, urea nitrogen and creatinine in outpatients >70 years of age with heart failure Am J Cardiol 96 705-9
  • [7] Cameron AV(2005)B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function J Card Fail 11 498-503
  • [8] Yandle TG(2002)Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction JAMA 288 1252-9
  • [9] Mair J(2002)Value of plasma B-Type natriuretic peptide measurement for heart disease screening in a Japanese population Heart 87 131-5
  • [10] Hammerer-Lercher A(2001)Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J Am Coll Cardiol 38 1934-41